Search
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[eculizumab] in June 2019 and [inebilizumab] in June 2020). … Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD.
Products: ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML, ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringeLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Fosdenopterin
go.drugbank.com/drugs/DB16628ApprovedIn 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … [L43075] In September 2022, the EMA approved the use of fosdenopterin.[L43372,L43433]
Drospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalDrospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. … [L7973] Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.
Synonyms: 6β,7β;15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactoneMixtures: ETINILESTRADIOLO E DROSPIRENONE DOC, ETINILESTRADIOLO E DROSPIRENONE DOCGENProbenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalProbenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Synonyms: 4-(N,N-Dipropylsulfamoyl)benzoesäure, 4-(Di-n-propylsulfamoyl)benzoesäureCategories: Compounds used in a research, industrial, or household setting, Preparations With No Effect on Uric Acid MetabolismElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalIt is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Palbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalPalbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigationallymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. … It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death.
Brepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs Used in Benign Prostatic Hypertrophy